Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma Meeting Abstract
| Authors: | Duell, J.; Abrisqueta, P.; Dreyling, M. H.; Gaidano, G.; González Barca, E.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Tournilhac, O.; Bakuli, A.; Amin, A.; Gurbanov, K.; Salles, G. A.; Nagy, Z. |
| Abstract Title: | Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.e19522 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: e19522 -- Meeting was also available virtually -- Source: Cinahl |
